|
1
|
Moretta A, Bottino C, Mingari MC, Biassoni
R and Moretta L: What is a natural killer cell? Nat Immunol. 3:6–8.
2002. View
Article : Google Scholar
|
|
2
|
Smyth MJ, Thia KY, Cretney E, et al:
Perforin is a major contributor to NK cell control of tumor
metastasis. J Immunol. 162:6658–6662. 1999.PubMed/NCBI
|
|
3
|
Lauwerys BR, Garot N, Renauld JC and
Houssiau FA: Cytokine production and killer activity of NK/T-NK
cells derived with IL-2, IL-15, or the combination of IL-12 and
IL-18. J Immunol. 165:1847–1853. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Smith BR, Rosenthal DS and Ault KA:
Natural killer lymphocytes in hairy cell leukemia: presence of
phenotypically identifiable cells with defective functional
activity. Exp Hematol. 13:189–193. 1985.
|
|
5
|
Biron CA, Nguyen KB, Pien GC, Cousens LP
and Salazar-Mather TP: Natural killer cells in antiviral defense:
function and regulation by innate cytokines. Annu Rev Immunol.
17:189–220. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rosenberg S: Lymphokine-activated killer
cells: a new approach to immunotherapy of cancer. J Natl Cancer
Inst. 75:595–603. 1985.PubMed/NCBI
|
|
7
|
Trinchieri G, Matsumoto-Kobayashi M, Clark
SC, Seehra J, London L and Perussia B: Response of resting human
peripheral blood natural killer cells to interleukin 2. J Exp Med.
160:1147–1169. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Goding SR, Yang Q, Knudsen KB, Potter DM
and Basse PH: Cytokine gene therapy using adenovirally transduced,
tumor-seeking activated natural killer cells. Hum Gene Ther.
18:701–711. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rosenberg SA, Lotze MT, Muul LM, et al:
Observations on the systemic administration of autologous
lymphokine-activated killer cells and recombinant interleukin-2 to
patients with metastatic cancer. N Engl J Med. 313:1485–1492. 1985.
View Article : Google Scholar
|
|
10
|
Yang Q, Hokland ME, Bryant JL, et al:
Tumor-localization by adoptively transferred,
interleukin-2-activated NK cells leads to destruction of
well-established lung metastases. Int J Cancer. 105:512–519. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Loza MJ and Perussia B: The IL-12
signature: NK cell terminal CD56+high stage and effector
functions. J Immunol. 172:88–96. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Maas RA, Dullens HF and Den Otter W:
Interleukin-2 in cancer treatment: disappointing or (still)
promising? A review. Cancer Immunol Immunother. 36:141–148. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Imboden M, Shi F, Pugh TD, et al: Safety
of interleukin-12 gene therapy against cancer: a murine
biodistribution and toxicity study. Hum Gene Ther. 14:1037–1048.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ji J, Li J, Holmes LM, et al:
Glycoinositol phospholipid-anchored interleukin 2 but not secreted
interleukin 2 inhibits melanoma yumor growth in mice. Mol Cancer
Ther. 1:1019–1024. 2002.PubMed/NCBI
|
|
15
|
Konstantinidis KV, Alici E, Aints A,
Christensson B, Ljunggren HG and Dilber MS: Targeting IL-2 to the
endoplasmic reticulum confines autocrine growth stimulation to
NK-92 cells. Exp Hematol. 33:159–164. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gurdon JB and Bourillot PY: Morphogen
gradient interpretation. Nature. 413:797–803. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cadigan KM: Regulating morphogen gradients
in the Drosophila wing. Semin Cell Dev Biol. 13:83–90. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lawrence PA and Struhl G: Morphogens,
compartments, and pattern: lessons from Drosophila? Cell.
85:951–961. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tabata T and Kornberg TB: Hedgehog is a
signaling protein with a key role in patterning Drosophila
imaginal discs. Cell. 76:89–102. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Teleman AA, Strigini M and Cohen SM:
Shaping morphogen gradients. Cell. 105:559–562. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vincent JP and Dubois L: Morphogen
transport along epithelia, an integrated trafficking problem. Dev
Cell. 3:615–623. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mann RK and Beachy PA: Novel lipid
modifications of secreted protein signals. Annu Rev Biochem.
73:891–923. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Guerrero I and Chiang C: A conserved
mechanism of Hedgehog gradient formation by lipid modifications.
Trends Cell Biol. 17:1–5. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vincent S, Thomas A, Brasher B and Benson
JD: Targeting of proteins to membranes through hedgehog
auto-processing. Nat Biotechnol. 21:936–940. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sanda MG, Restifo NP, Walsh JC, et al:
Molecular characterization of defective antigen processing in human
prostate cancer. J Natl Cancer Inst. 87:280–285. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Robertson MJ and Ritz J: Biology and
clinical relevance of human natural killer cells. Blood.
76:2421–2438. 1990.PubMed/NCBI
|
|
27
|
Albertsson PA, Basse PH, Hokland M, et al:
NK cells and the tumour microenvironment: implications for NK-cell
function and anti-tumour activity. Trends Immunol. 24:603–609.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Basse PH, Whiteside TL and Herberman RB:
Cancer immunotherapy with interleukin-2-activated natural killer
cells. Mol Biotechnol. 21:161–170. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Law TM, Motzer RJ, Mazumdar M, et al:
Phase III randomized trial of interleukin-2 with or without
lymphokine-activated killer cells in the treatment of patients with
advanced renal cell carcinoma. Cancer. 76:824–832. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kammula US, White DE and Rosenberg SA:
Trends in the safety of high dose bolus interleukin-2
administration in patients with metastatic cancer. Cancer.
83:797–805. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Herberman RB, Reynolds CW and Ortaldo JR:
Mechanism of cytotoxicity by natural Killer (NK) cells. Annu Rev
Immunol. 4:651–680. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Skoskiewicz MJ, Colvin RB, Schneeberger EE
and Russell PS: Widespread and selective induction of major
histocompatibility complex-determined antigens in vivo by gamma
interferon. J Exp Med. 162:1645–1664. 1985. View Article : Google Scholar : PubMed/NCBI
|
